Plasma glycoprotein V levels in the general population: Normal distribution, associated parameters and implications for clinical studies

Summary

Soluble glycoproteinV (sGPV) isa new plasma marker of thrombosis released from the platelet surface by thrombin. sGPV levels are increased in patients with atherothrombotic diseases, but the determinants of sGPV levels are unknown in the general population. Identification of these potential confounding factors is needed for correct design and analysis of clinical studies on cardiovascular diseases.The aim of this study was to determine the normal range of plasma values and the factors controlling sGPV levels in a population of normal individuals.Three hundred blood donors were recruited at the Etablissement Français du Sang-Alsace for the measurement of plasma levels of sGPV, platelet factor 4 (PF4), thrombin-antithrombin complexes (TAT) and D-dimers.The plasma level of sGPV was (median [interquartile range]) 27.5 [23.5–34.4] µg/l and displayed a Gaussian distribution. sGPV had a lower interindividual coefficient of variation (33%) than PF4 (176%), TAT (87%) or D-dimers (82%). sGPV levels were independent of age and sex but sensitive to red cell (r=0.412; p<0.0001) and platelet counts (r=0.267; p=0.001), total cholesterol (r=−0.313; p<0.0001), food intake (r=0.184; p=0.0014) and smoking (r=−0.154; p=0.039). Contrary to PF4 and TAT, sGPV did not differ between venous and arterial blood samples of 12 healthy individuals. Red cell and platelet counts, total cholesterol, current smoking and recent food intake are important determinants of sGPV levels and must be taken into account in clinical studies using sGPV as a thrombosis marker. Normal distribution of sGPV levels in the general population supports its use in clinical applications.

Keywords

Glycoprotein V - GPV - platelet - thrombosis marker

• References

• 1 Boisclair MD, Ireland H, Lane DA. Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood Rev 1990; 04: 25-40.
• 2 Bauer KA. Activation markers of coagulation. Baillieres Best Pract Res Clin Haematol 1999; 12: 387-406.
• 3 Gyongyosi M, Glogar D, Weidinger F. et al. Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-st-segment elevation myocardial infarction. Am Heart J 2004; 147: 158-64.
• 4 Nagao T, Hamamoto M, Kanda A. et al. Platelet activation is not involved in acceleration of the coagulation system in acute cardioembolic stroke with nonvalvular atrial fibrillation. Stroke 1995; 26: 1365-8.
• 5 Kelly J, Rudd A, Lewis RR. et al. Plasma D-dimers in the diagnosis of venous thromboembolism. Arch Intern Med 2002; 162: 747-56.
• 6 Niewiarowski S, Thomas DP. Platelet factor 4 and adenosine diphosphate release during human platelet aggregation. Nature 1969; 222: 1269-70.
• 7 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-6.
• 8 Lane DA, Preston FE, VanRoss ME. et al. Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation. Br J Haematol 1978; 40: 609-15.
• 9 Fareed J, Hoppensteadt DA, Leya F. et al. Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. Clin Chem 1998; 44: 1845-53.
• 10 Gershlick AH. Are there markers of the bloodvessel wall interaction and of thrombus formation that can be used clinically?. Circulation 1990; 81: I28-34.
• 11 Giansante C, Fiotti N, Cattin L. et al. Fibrinogen, D-dimer and thrombin-antithrombin complexes in a random population sample: relationships with other cardiovascular risk factors. Thromb Haemost 1994; 71: 581-6.
• 12 Lee AJ, Fowkes GR, Lowe GD. et al. Determinants of fibrin D-dimer in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1995; 15: 1094-7.
• 13 Cadroy Y, Pierrejean D, Fontan B. et al. Influence of aging on the activity of the hemostatic system: prothrombin fragment 1+2, thrombin-antithrombin III complexes and D-dimers in 80 healthy subjects with age ranging from 20 to 94 years. Nouv Rev Fr Hematol 1992; 34: 43-6.
• 14 Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006; 113: 2335-62.
• 15 Blann AD, Lanza F, Galajda P. et al. Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis--the influence of aspirin and cigarette smoking. Thromb Haemost 2001; 86: 777-83.
• 16 Kamath S, Blann AD, Chin BS. et al. A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy. Eur Heart J 2002; 23: 1788-95.
• 17 Aleil B, Mossard JM, Wiesel ML. et al. Increased plasma levels of soluble platelet glycoproteinV in patients with acute myocardial infarction. J Thromb Haemost 2003; 01: 1846-7.
• 18 Morel O, Hugel B, Jesel L. et al. Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists. J Thromb Haemost 2004; 02: 1118-26.
• 19 Morel O, Hugel B, Jesel L. et al. Sustained elevated amounts of circulating procoagulant membrane microparticles and soluble GPV after acute myocardial infarction in diabetes mellitus. Thromb Haemost 2004; 91: 345-53.
• 20 Tan KT, Tayebjee MH, Macfadyen RJ. et al. Relation of platelet activation to coronary angiographic severity and collateralization. Am J Cardiol 2005; 96: 208-10.
• 21 Atalar E, Haznedaroglu IC, Kilic H. et al. Increased soluble glycoproteinV concentration during the acute onset of unstable angina pectoris in association with chronic cigarette smoking. Platelets 2005; 16: 329-33.
• 22 Dempfle CE, Kaden JJ, Haase KK. et al. Course of indicators of thrombin activity in the early phase of acute myocardial infarction: effect of fibrinolytic therapy and acute percutaneous coronary angioplasty. Thromb Haemost 2003; 90: 147-54.
• 23 Wolff V, Aleil B, Giroud M. et al. Soluble platelet glycoprotein V is a marker of thrombosis in patients with ischemic stroke. Stroke 2005; 36: e17-9.
• 24 Modderman PW, Admiraal LG, Sonnenberg A. et al. Glycoproteins V and Ib-IX form a noncovalent complex in the platelet membrane. J Biol Chem 1992; 267: 364-9.
• 25 Moog S, Mangin P, Lenain N. et al. Platelet glycoprotein V binds to collagen and participates in platelet adhesion and aggregation. Blood 2001; 98: 1038-46.
• 26 Ramakrishnan V, Reeves PS, DeGuzman F. et al. Increased thrombin responsiveness in platelets from mice lacking glycoprotein V. Proc Natl Acad Sci USA 1999; 96: 13336-41.
• 27 Lanza F, Morales M, de La Salle C. et al. Cloning and characterization of the gene encoding the human platelet glycoprotein V. A member of the leucine-rich glycoprotein family cleaved during thrombin-induced platelet activation. J Biol Chem 1993; 268: 20801-7.
• 28 Rabie T, Strehl A, Ludwig A. et al. Evidence for a role of ADAM17 (TACE) in the regulation of platelet glycoprotein V. J Biol Chem 2005; 280: 14462-8.
• 29 Berndt MC, Phillips DR. Purification and preliminary physicochemical characterization of human platelet membrane glycoprotein V. J Biol Chem 1981; 256: 59-65.
• 30 Azorsa DO, Moog S, Ravanat C. et al. Measurement of GPV released by activated platelets using a sensitive immunocapture ELISA--its use to follow platelet storage in transfusion. Thromb Haemost 1999; 81: 131-8.
• 31 Ravanat C, Freund M, Mangin P. et al. GPV is a marker of in vivo platelet activation--study in a rat thrombosis model. Thromb Haemost 2000; 83: 327-33.
• 32 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
• 33 Iversen LH. Pre-analytical variation in the measurements of sensitive markers of coagulation and fibrinolysis: the influence of venipuncture and mixing of blood. Haemostasis 1997; 27: 119-24.
• 34 Hafner G, Schinzel H, Ehrenthal W. et al. Influence of blood sampling from venipunctures and catheter systems on serial determinations of prothrombin activation fragment 1 + 2 and thrombin-antithrombin III complex. Ann Hematol 1993; 67: 121-5.
• 35 Strauss W, Cella G, Myers C. et al. Serial determinations of PF4 and beta TG: comparisons between multiple venipunctures vs a catheter infusion system. Thromb Haemost 1988; 59: 491-4.
• 36 Fox JEB. Shedding of adhesion receptors from the surface of activated platelets. Blood Coagul Fibrinolysis 1994; 05: 291-304.
• 37 Wicki AN, Clemetson KJ. Structure and function of platelet membrane glycoproteins Ib and V. Effects of leukocyte elastase and other proteases on platelets response to von Willebrand factor and thrombin. Eur J Biochem 1985; 153: 1-11.
• 38 Michelson AD, Benoit SE, Furman MI. et al. The platelet surface expression of glycoprotein V is regulated by two independent mechanisms: proteolysis and a reversible cytoskeletal-mediated redistribution to the surface-connected canalicular system. Blood 1996; 87: 1396-408.
• 39 Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001; 86: 222-32.
• 40 Weiss HJ. Flow-related platelet deposition on subendothelium. Thromb Haemost 1995; 74: 117-22.
• 41 Andrews DA, Low PS. Role of red blood cells in thrombosis. Curr Opin Hematol 1999; 06: 76-82.